Parveen Kundu
About Parveen Kundu
Parveen Kundu has 8 years in corporate governance. Holds Partner and Designated Partner roles. Currently with 3 companies, including Mitti Theranostics Llp and Nuclear Medsystems India Llp. Formerly with 2 companies, such as Nuclear Medsystems India Private Limited. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Mitti Theranostics Llp
ABZ-5172
|
Partner | 19 Dec 2022 | 2022 | Active |
Rohtak Nuclear Medcare Llp
AAK-8892
|
Designated Partner | 16 Oct 2017 | 2017 | Active |
Nuctherain Private Limited
U72100HR2025PTC136634
|
Director | 18 Sep 2025 | 2025 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Nuclear Medsystems India Private Limited
U52520DL2021PTC382732
|
Director | 24 Jun 2021 | 2021 | Active |
Nuclear Medsystems India Llp
AAL-3600
|
Designated Partner | 11 Dec 2017 | 2017 | Converted To Cmp And Dissolved |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Parveen Kundu
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Parveen Kundu
Parveen Kundu has 8 years in corporate governance. Holds Partner and Designated Partner roles. Currently with 3 companies, including Mitti Theranostics Llp and Nuclear Medsystems India Llp. Formerly with 2 companies, such as Nuclear Medsystems India Private Limited. Engaged in General Business. Contributes to corporate operations.
Parveen Kundu is associated with 3 companies as Partner and Designated Partner.
Parveen Kundu has expertise in General Business.
Parveen Kundu has 8 years in corporate governance.